AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33610123
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with placebo throughout (arm A, reference)
Trial: 32218424
Drug: Hoodia Parviflora
RxNorm normalized name: HOODIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoodia Parviflora (H. Parviflora) at 9 mg + 200 mg of fructo‐oligosaccharides, taken twice a day for 4 weeks
Trial: 35989963
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation + robot-assisted hand therapy (HandTutor) for 1 hour during each session, 3 h/day, 2 days/week for 5 weeks
Trial: 33030570
Drug: Lipid-lowering medications
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering medications (LLMs)
Trial: 32854145
Drug: Immunotherapy (BILITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (BILITE design)
Trial: 35420710
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning predictive model for heavy drinking during the first month of treatment
Trial: 35420710
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning predictive model for heavy drinking during the last month of treatment
Trial: 35420710
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning predictive model for heavy drinking between weekly/bi-weekly sessions
Trial: 32096313
Drug: RG-101 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 6 weeks
Trial: 32096313
Drug: RG-101 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 9 weeks
Trial: 32096313
Drug: RG-101 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 12 weeks
Trial: 32096313
Drug: GSK2878175 long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2878175 long-acting injectable at 400 mg
Trial: 38756738
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment
Trial: 35467962
Drug: Breathing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing and relaxation exercises performed via telerehabilitation, twice daily for 4 weeks, with one session supervised by a physiotherapist.
Trial: 33940496
Drug: Hippotherapy (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (16 sessions of 30 minutes, twice a week)
Trial: 32634656
Drug: Modified photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified photodynamic therapy (M-PDT)
Trial: 36091003
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg, intravenous drip, once every 3 weeks) combined with apatinib (250 mg, oral administration, once a day) plus capecitabine (1000 mg/m2, twice a day; after 2 weeks of oral administration, the drug was stopped for 1 week; course of treatment, 3 weeks)
Trial: 33835175
Drug: E‐WORTH (5‐session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐WORTH (5‐session culturally tailored group‐based intervention including a 1‐hour individual HIV testing and orientation session and 4 weekly 90‐minute group sessions)
Trial: 33028310
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of magnesium sulfate for severe pre-eclampsia
Trial: 33028310
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of anti-hypertensive drugs for severe pre-eclampsia
Trial: 33028310
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of prophylactic use of aspirin to prevent pre-eclampsia
Trial: 36501186
Drug: OliPhenolia® (OliP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OliPhenolia® (OliP) 2 × 28 mL∙d−1 for 16 days
Trial: 33115894
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT, 9000 lux, 5000 K)
Trial: 33115894
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light therapy (DRLT, 100 lux, 2700 K)
Trial: 34391230
Drug: Lymphatic drainage
RxNorm normalized name: PEPPERMINT 13 mg in 50 mL / SAGE OIL 5.3 mg in 50 mL TOPICAL OIL [Swelling Solution - improving lymphatic drainage]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic drainage therapy (LDT) applied for 45 minutes by an experienced physical therapist.
Trial: 34391230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CT: rest) received 45 minutes supine on the treatment table.
Trial: 32239322
Drug: Pirfenidone (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (2400 mg/day)
Trial: 38354688
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy
Trial: 34425828
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk cell fractions (BMCFs) administered within 6 to 12 hours after birth
Trial: 35411579
Drug: TBP‐PI‐HBr test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBP‐PI‐HBr test (registration tablet)
Trial: 35411579
Drug: TBP‐PI‐HBr reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBP‐PI‐HBr reference (clinical trial tablet)
Trial: 35411579
Drug: TBP‐PI‐HBr test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBP‐PI‐HBr test (registration tablet) under fed conditions
Trial: 35411579
Drug: TBP‐PI‐HBr test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBP‐PI‐HBr test (registration tablet) and reference (clinical trial tablet)
Trial: 34655316
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg plus 60 mg codeine
Trial: 35545724
Drug: Single-agent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent treatment of physician’s choice (TPC)
Trial: 35545724
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) with prior CDK4/6 inhibitors
Trial: 35545724
Drug: Single-agent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent treatment of physician’s choice (TPC) with prior CDK4/6 inhibitors
Trial: 35905305
Drug: Buccally absorbed
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccally absorbed CBD (25 mg 3 times a day if <80 kg, or 50 mg 3 times a day if >80 kg) for 14 days postoperatively
Trial: 34226219
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) plus best practice treatment
Trial: 34226219
Drug: Best practice
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practice treatment
Trial: 36063058
Drug: Conventional open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional open surgical treatment (Group 1)
Trial: 34763338
Drug: 3% Hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Hypertonic Saline (HS), 5 ml/kg as continuous infusion, titrated every 6 hours to achieve serum sodium <160
Trial: 34763338
Drug: 20% Mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Mannitol (MT), 1 g/kg as IV bolus, repeated every six hours
Trial: 35078404
Drug: Time between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time between preparation and colonoscopy
Trial: 33998168
Drug: High-density subthreshold
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density subthreshold micropulse laser (HSML) treatment
Trial: 32210537
Drug: DEX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX group (loading dose of DEX at 0.5 μg/kg within 10 min, followed by infusion of DEX at 0.5 μg/kg/h until the end of surgery and PCIA for 2 days with DEX plus sufentanil)
Trial: 33323237
Drug: Sensor-assisted pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-assisted pump therapy
Trial: 33653300
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus medication self-management intervention
Trial: 33119861
Drug: SDZ-ADL 40
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SDZ-ADL 40 mg subcutaneous every other week from Week 0 to Week 24, continued for patients with moderate response at Week 24 (n = 159)
Trial: 33523513
Drug: tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tildrakizumab 100 mg
Trial: 33523513
Drug: tildrakizumab 200
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tildrakizumab 200 mg
Trial: 35691324
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses, administered 28 days or 84 days apart.
Trial: 35691324
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (capsular group B meningococcal vaccine).
Trial: 35987819
Drug: Oral enteric
RxNorm normalized name: Ascriptin Enteric Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteric coating lactoferrin (700 mg/day for at least 28 consecutive days)
Trial: 33949022
Drug: Surgery Start
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery Start Time (SST) - Afternoon implant placement
Trial: 33949022
Drug: Pre-placement ridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-placement ridge augmentation
Trial: 32268191
Drug: Fast disintegrating
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast disintegrating and dissolving Aspirin® tablet (FDDT)
Trial: 32268191
Drug: Regular Aspirin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Aspirin® tablet (RT)
Trial: 35718771
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (SBP 110–120 mmHg) in SPRINT
Trial: 35718771
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (SBP 120–130 mmHg) in SPRINT
Trial: 35718771
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (SBP 110–120 mmHg) in ACCORD-BP
Trial: 35718771
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (SBP 120–130 mmHg) in ACCORD-BP
Trial: 32252803
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise augmented cognitive behaviour therapy
Trial: 33170262
Drug: Novel cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel cancer therapies
Trial: 33434615
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for Alcohol Use Disorder (AUD)
Trial: 32591820
Drug: (lipo)glycopeptides (LGP/GPs)
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (lipo)glycopeptides (LGP/GPs) in combination with β-lactams
Trial: 36159218
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic chemotherapy
Trial: 36382660
Drug: Oral +
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral + photograph counseling
Trial: 34715821
Drug: Transdermal rivastigmine
RxNorm normalized name: rivastigmine Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rivastigmine for 12 months
Trial: 33256382
Drug: Hyperimmune plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperimmune plasma (250-300 ml units with neutralizing antibodies titer ≥1:160)
Trial: 38049713
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDFT)
Trial: 34959789
Drug: 2.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/day of Neptune krill oilTM (550 mg EPA/DHA and 150 mg choline)
Trial: 35536441
Drug: Chlormethine gel
RxNorm normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlormethine gel
Trial: 35536441
Drug: Chlormethine ointment
RxNorm normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlormethine ointment
Trial: 35416910
Drug: Edoxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (15 mg once daily)
Trial: 33917587
Drug: 4-mm short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mm short implants
Trial: 33917587
Drug: 10-mm standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mm standard implants
Trial: 33001139
Drug: Oral dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexmedetomidine (700 mcg)
Trial: 39163362
Drug: PCT-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided treatment
Trial: 35899204
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I; i-Sleep)
Trial: 33069109
Drug: 4-day stimulus–response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day stimulus–response compatibility (SRC) approach bias modification treatment
Trial: 33136517
Drug: SGLT2 Inhibition
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 Inhibition in Combination with Loop Diuretics
Trial: 35580546
Drug: 4F-PCC for
RxNorm normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4F-PCC for factor Xa inhibitors
Trial: 35580546
Drug: 4F-PCC for
RxNorm normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4F-PCC for warfarin
Trial: 33413599
Drug: Continuous warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous warfarin administration
Trial: 33413599
Drug: Heparin bridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bridge therapy
Trial: 32152915
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of oral absorption using GastroPlus™ and dissolution data
Trial: 33511988
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (10,000 lux for 30 min/day)
Trial: 33511988
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (inactivated negative ion generator)
Trial: 32236950
Drug: Chlorambucil monotherapy
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil monotherapy
Trial: 32044505
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy (control group)
Trial: 32028117
Drug: GA 40
RxNorm normalized name: Potiga 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA 40 mg/mL three-times-weekly (TIW)
Trial: 32028117
Drug: GA 20
RxNorm normalized name: Potiga 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA 20 mg/mL once-daily (QD)
Trial: 32203978
Drug: Canakinumab (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months
Trial: 35572837
Drug: Moxibustion instrument
RxNorm normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion instrument combined with intermediate frequency electrostatic therapy
Trial: 35572837
Drug: Medium-frequency treatment
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-frequency treatment (Control)
Trial: 36324229
Drug: Interferon β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β‐1a (7.5‐30 μg)
Trial: 36324229
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon β‐1a (31.25‐125 μg)
Trial: 32095954
Drug: eHealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth treatment for urinary incontinence (UI)
Trial: 35382796
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (CamAPS FX application, Dana Diabecare RS insulin pump)
Trial: 35382796
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring (CGM) with usual insulin delivery (Dexcom G6)
Trial: 33551858
Drug: Control condition:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition: treatment as usual.
Trial: 33212067
Drug: Two-dose CYD-TDV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Trial: 33212067
Drug: Three-dose CYD-TDV
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Trial: 33212067
Drug: Two-dose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose placebo (administered at months 0 and 6) and one dose of CYD-TDV (administered at month 12)
Trial: 32792244
Drug: SSS07, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSS07, a humanized rabbit anti-human TNF alpha antibody
Trial: 33066009
Drug: Choline supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplement (choline bitartrate, 400 mg choline/day)
Trial: 32941098
Drug: Placebo; at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; at least one placebo administered to participants.
Trial: 32549100
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine group (10% lidocaine oropharyngeal spray, five minutes before laryngoscopy and endotracheal intubation)
Trial: 32549100
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no lidocaine spray)
Trial: 33197226
Drug: Continued chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued chemotherapy
Trial: 33216632
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (3 g per day for 12 weeks)
Trial: 36297060
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester supplement (KME) 25 g
Trial: 37365597
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy (nCT)
Trial: 34750146
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg ASA
Trial: 34750146
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg ASA
Trial: 36018753
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccines with 0.10, 0.33, or 1.0 µg of recombinant SARS-CoV-2 spike protein, with or without GM-CSF
Trial: 36018753
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccines without GM-CSF
Trial: 34219257
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D1–25 supplementation for high-risk patients, routine daily calcium samples until 48 hours post-surgery.
Trial: 34219257
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily calcium samples for low-risk patients until 48 hours post-surgery.